摘要
目的:评价莫西沙星与头孢哌酮/舒巴坦治疗老年医院内获得性肺炎的临床疗效与安全性。方法:将47例老年医院获得性肺炎患者随机分成治疗组27例和对照组20例,分别给予莫西沙星注射液和头孢哌酮/舒巴坦注射液治疗。结果:治疗组与对照组的临床有效率分别为85%和70%,两组对比差异无统计学意义(P>0.05);治疗组与对照组的细菌学清除率分别为80.1%和76.9%,两组对比差异无统计学意义(P>0.05);治疗组与对照组的不良反应基本相同。结论:莫西沙星对治疗老年医院获得性肺炎的临床疗效确切、安全性高。
Objective To evaluate the clinical effect and safety in the treatment of nosocomial pneumonia by avelox （moxifloxacin HCL） and Cefperazone-Sulbactam. Methods Forty-seven patients with nosocomial pneumonia were randomly divided into control group （20 cases） by Cefperazone- Sulbactam and treatment group （27 cases） by avelox（moxifloxacin HCL）. Results The rate of clinical effect was 85% and 70% in treatment group and control group （P〉0. 05）. The rate of bacteria clearance was 80. 1% and 76.9% in treatment and control group（P〉0. 05）. Adverse drug reaction of two groups was nearly the same. Conclusion Avelox （moxifloxacin HCL） is effective and safe for nosocomial pneumonia.
出处
《实用诊断与治疗杂志》
2007年第1期23-24,共2页
Journal of Practical Diagnosis and Therapy
